Heinrich and colleagues’ elegant study also identified PDGFRα-activating mutations in a subset of human gastrointestinal stromal tumors, for which PDGFRα may prove to be a useful molecular marker and therapeutic target [47]. The gene discussed is PDGFRA; the disease is gastrointestinal stromal tumor.